Skip to Content

Posts tagged with "The Dark Side"

  • Business and Markets

    The Dark Side of a Wonderful Investment Story

    Biopharma investing has been a constantly erupting geyser of cash these last few years, and wherever there is that amount of money flying around, you will find people ready to help make it disappear. And you’ll find people who are willing to stretch the truth in any way that they find necessary to get in… Read More
  • The Dark Side

    India Tries to Deal With Predatory Publishers

    There’s more activity on the predatory journal front. A large investigation reported recently that the number of papers put out by the five largest publishers in this category has tripled since 2015, so there’s clearly an expanding market for such “services”. Among the elite (by which I mean the top layer of this pond scum) Read More
  • Current Events

    Deliberate Vaccine Misinformation

    Over on my Twitter feed, which veers off-topic a bit more often than this blog, I had a series of tweets the other day about troll/bot accounts. And as fate would have it, that very subject now intersects more closely with a focus on biomedical news. This new paper in the American Journal of Public… Read More
  • Inorganic Chemistry

    A Room Temperature Superconductor? Well. . .

    Superconductivity is one of those places where chemistry and physics cross paths. That’s especially true as people search for higher-temperature materials, because that seems to involve more and more complex synthesis and characterization of the results. Very tiny changes in conditions or starting materials can make for huge differences in th… Read More
  • The Dark Side

    How Many Doctored Papers Are Out There?

    Just how much crap is out there in the scientific literature? “Quite a bit” comes the answer from anyone with real experience of it, but that’s not too quantitative. Here, though is an analysis of one (perfectly respectable) journal of its own output, and the results are. . .well, they range from “pretty bad” to… Read More
  • Business and Markets

    Welcome to Right to Try

    Update: Brainstorm has now abandoned their Right-to-Try approach. Who’s next? That didn’t take long. That didn’t take long at all. The federal “Right to Try” bill was just signed the other week, and we already have a company that’s willing – no, eager – to try it out. I will now cruelly caricature som… Read More
  • General Scientific News

    Science Reform in China

    There have been all sorts of scientific scandals involving faked journal articles, faked peer reviews, duplicated papers and figures, etc. over the last few years. It’s been a running battle: our current technologies allow for these things to be done more easily, but caught more easily as well. And a pretty significant share of these… Read More
  • Snake Oil

    A New Low for Dr. Oz

    Pardon me this morning while I rant a little. In fact, it’s worse: pardon me while I rant a little about something that I’ve ranted about before. I refer to that disgrace to the medical profession, Dr. Mehmet Oz. I haven’t mentioned him on the site in a while, because really, why bother? Nothing that… Read More
  • Chemical News

    Ark Pharm’s Shady Side

    Once in a while we have discussions of chemical suppliers around here – but we haven’t had one like this. On Friday afternoon, word came out that Ark Pharm, a reasonably well-known firm out of Chicago, had been raided by the DEA. That becomes abundantly clear if you try to access the company’s web site. Read More
  • Infectious Diseases

    Fluoroquinolone Trouble Untangled

    The fluoroquinolone antibiotics are important drugs indeed – ciprofloxacin is probably the most famous of the bunch, but there’s a whole series of them, and they’re widely used for serious bacterial infections. (I last wrote about them here, with the various arguments about how they were developed in the first place). But for many… Read More
123...